SCP
XENE icon

Sender Company & Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Sender Company & Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,215
Closed -$382K – 107
2021
Q4 		$382K Buy
+12,215
New +$365K 0.2% 81

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sender Company & Partners's XENE Position: Q1 2022 in Review

Sender Company & Partners sold out of Xenon Pharmaceuticals (XENE) in Q1 2022, closing a stake of 12,215 shares — an estimated $382K sold.

Sender Company & Partners first reported a position in XENE in Q4 2021 and held it in 1 quarter. The position peaked at $382K in Q4 2021. 133 funds tracked by Wall St. Rank hold XENE as of Q1 2022.

  • Sender Company & Partners reported no remaining Xenon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 12,215 Xenon Pharmaceuticals shares in Q1 2022, an estimated $382K.
  • Sender Company & Partners first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Xenon Pharmaceuticals position peaked at $382K in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.